Thermoregulatory Support Supplements
Certainty: 0.30. Cold thermogenesis requires fatty acid oxidation for UCP1-mediated heat production. L-carnitine transports fatty acids into mitochondria. ME/CFS patients may have functional carnitine deficiency impairing BAT activation. Supplementation (2 g/day) may improve cold tolerance, though BAT activity declines with age in the typical ME/CFS demographic. Falsifiable: L-carnitine vs placebo x 12 weeks increases cold tolerance by Ξ3Β°C and improves fatty acid oxidation markers (CPT1 activity); effect magnitude correlates with baseline carnitine status. No ME/CFS data; extrapolated from BAT physiology and cold intolerance mechanism (ch10:Could Cold Intolerance Reflect Failed Brown Adipose Tissue Activation via Sympathetic Dysfunction?).
Certainty: 0.35. Magnesium is a physiological calcium antagonist in vascular smooth muscle, producing vasodilation. If ET-1-mediated tonic vasoconstriction contributes to thermoregulatory failure (ch10:Tonic Cutaneous Vasoconstriction Bias Explains Dual Heat+Cold Intolerance), magnesium glycinate (400 mg/day elemental) may partially counteract ET-1 vasoconstriction and improve vasomotor flexibility. Glycinate form provides glycine for synergistic ET-1 reduction and sleep thermoregulation. Falsifiable: magnesium glycinate vs placebo x 8 weeks reduces ET-1 by >15% and improves skin temperature rhythm amplitude by >20%. No ME/CFS thermoregulatory data; magnesium deficiency documented in a subset of ME/CFS patients.
Certainty: 0.30. Thermoregulation is ATP-expensive: sweating (eccrine gland ion transport), shivering (burst mitochondrial output), and vasomotion (smooth muscle ATP turnover) all draw on cellular energy reserves. Creatine (5 g/day) buffers the ATP/ADP ratio via phosphocreatine shuttle. In ME/CFS, where mitochondrial reserve is constrained, creatine may provide a rapid-access energy buffer that delays fatigue during thermal stress. Falsifiable: creatine vs placebo x 12 weeks increases ATP levels during standardized thermal challenge and reduces subjective fatigue during heat/cold exposure by >30%. No ME/CFS thermoregulation-specific data; creatine safety profile is well-established but efficacy in ME/CFS fatigue is contested.
Certainty: 0.30. Citrulline (6 g/day) bypasses first-pass hepatic metabolism of arginine, directly increasing nitric oxide production via the citrulline-arginine-NO pathway. NO-mediated vasodilation may counteract ET-1-mediated vasoconstriction, improving cutaneous perfusion for heat dissipation. More effective than direct arginine supplementation. Falsifiable: citrulline vs placebo x 8 weeks improves flow-mediated dilation by >20% and increases heat tolerance vasodilation by >25%. No ME/CFS-specific data; endothelial dysfunction documented in ME/CFS; NO pathway activation untested.
Certainty: 0.30. Vitamin D regulates vascular tone by inhibiting renin-angiotensin signaling and upregulating endothelial NO synthase. It also modulates HSP70 expression. ME/CFS patients have elevated vitamin D deficiency prevalence. Correction (target serum 25(OH)D 50β80 ng/mL) may improve vascular tone and support HSP70-mediated thermotolerance. Falsifiable: vitamin D3 supplementation achieving target serum levels vs placebo x 12 weeks improves vascular tone markers and increases HSP70 protein by >30%; effect correlates with baseline deficiency. No ME/CFS thermoregulation-specific data.
Quercetin (500 mg BID) stabilizes mast cells and desensitizes TRPV1 receptors in preclinical models β the same TRPV1-mast cell axis implicated in heat-triggered MCAS exacerbation in ME/CFS (Section Mast Cell Mediators and Histaminergic Symptom Generation). If heat-triggered flushing, gastrointestinal symptoms, and orthostatic worsening are TRPV1-mediated in MCAS+ ME/CFS patients, quercetin could reduce heat-triggered symptom burden without requiring thermal avoidance. Falsifiable: quercetin vs placebo x 8 weeks in MCAS+ ME/CFS reduces heat-triggered symptom severity by >40% (validated MCAS symptom diary during standardized heat challenge). No ME/CFS quercetin thermoregulation data; MCAS literature is from general population. Falsified if quercetin does not reduce heat-triggered symptom severity by at least 40% versus placebo in a randomized trial, indicating the TRPV1-mast cell axis is not the dominant driver of heat intolerance.
Certainty: 0.25. Alpha-lipoic acid (ALA, 600 mg/day) is a mitochondrial cofactor and antioxidant. It activates Nrf2-dependent antioxidant enzymes (HO-1, NQO1) but does NOT directly upregulate HSP70 β HSP70 transcription is driven by HSF1, not Nrf2. Any HSP70 benefit from ALA would be indirect: reduced oxidative stress lowers the threshold for HSF1 activation during subsequent thermal challenge, improving heat-shock competence without directly inducing HSP70. Falsifiable: ALA over 8 weeks reduces mitochondrial ROS by 30% and improves thermal-HSP70 inducibility (measured post-WBH challenge) by 25%. No ME/CFS ALA thermoregulation data; short half-life (~30 min) may limit sustained oxidative stress reduction.
Certainty: 0.30. Glycine (3 g/day) is a collagen component and acts as a vasodilator via glycine receptors on endothelial cells. It may reduce ET-1 production and improve vascular tone, supporting vasomotor flexibility. Glycine is already discussed for sleep thermoregulation (Section Sleep Management) β thermoregulatory vascular benefit during waking hours would extend its utility. Falsifiable: glycine over 8 weeks reduces ET-1 by 15% and improves skin temperature rhythm amplitude by 20%. No ME/CFS glycine-vascular data; sleep benefit supported by one RCT.
Certainty: 0.20. Sulforaphane (broccoli sprout extract, 30β60 mg/day) is a potent Nrf2 activator that upregulates antioxidant enzymes (HO-1, NQO1, glutathione synthesis). It does NOT directly upregulate HSP70 β HSP70 transcription is driven by HSF1, not Nrf2. Any HSP70 benefit would be indirect: reduced oxidative stress lowers the threshold for HSF1-dependent HSP70 induction during subsequent thermal challenge. Sulforaphane also exhibits hormetic properties (inducing oxidative stress at high doses), potentially worsening oxidative burden β a caution for already-stressed ME/CFS patients. Falsifiable: sulforaphane over 8 weeks activates Nrf2 targets more than 3-fold and indirectly improves thermal-HSP70 inducibility by 20%. No ME/CFS sulforaphane data.
Certainty: 0.25. Taurine (1β3 g/day) stabilizes mitochondrial membranes, reduces oxidative stress, and modulates calcium handling β all processes stressed during thermoregulatory work. While taurineβs mitochondrial-protective and calcium-modulating effects are well-characterized, no ME/CFS thermoregulation-specific data exist. Falsifiable: taurine over 12 weeks increases mitochondrial membrane potential stability during controlled heat challenge by >25%. Taurine is generally safe and inexpensive, making it a low-risk adjunct.